Haesook T. Kim
Harvard University
Internal medicineSurgeryOncologyImmunologyT cellHematopoietic stem cell transplantationLeukemiaFludarabineGraft-versus-host diseaseBusulfanRegimenStem cellTacrolimusTransplantationClinical trialMedicineIL-2 receptorBiologyCumulative incidenceImmune systemGastroenterology
368Publications
74H-index
14kCitations
Publications 366
Newest
#1Christopher J. Gibson (Harvard University)H-Index: 22
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. R. Coleman Lindsley (Harvard University)H-Index: 26
view all 29 authors...
PURPOSEClonal hematopoiesis (CH) can be transmitted from a donor to a recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since it...
Source
#1Pavan BachireddyH-Index: 17
#2Elham Azizi (Columbia University)H-Index: 10
Last. Satyen H. Gohil (Harvard University)H-Index: 10
view all 22 authors...
Summary null null To elucidate mechanisms by which T cells eliminate leukemia, we study donor lymphocyte infusion (DLI), an established immunotherapy for relapsed leukemia. We model T cell dynamics by integrating longitudinal, multimodal data from 94,517 bone marrow-derived single T cell transcriptomes in addition to chromatin accessibility and single T cell receptor sequencing from patients undergoing DLI. We find that responsive tumors are defined by enrichment of late-differentiated T cells b...
Source
#1Mary Nauffal (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Vincent T. Ho (Harvard University)H-Index: 98
view all 11 authors...
Hepatic veno-occlusive disease or sinusoidal obstructive syndrome (VOD/ SOS) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Defibrotide is the only FDA-approved medication for the management of severe VOD/ SOS after HSCT. We report our center's experience with commercially available defibrotide as treatment for patients with VOD/SOS. We retrospectively identified 28 cases of VOD/ SOS, based on the European Society for Blood and Marrow Transplantation criter...
Source
#1Jacqueline S. Garcia (Harvard University)H-Index: 16
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Joseph H. Antin (Harvard University)H-Index: 135
view all 25 authors...
Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. This phase 1 study investigated the recommended phase 2 (RP2D) of venetoclax, a BCL-2 selective inhibitor, when added to FluBu2 in adult patients with high risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and MDS/myeloproliferative neoplasms (MPN) un...
Source
#1Katie Maurer (Harvard University)H-Index: 1
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Mahasweta Gooptu (Harvard University)H-Index: 10
view all 18 authors...
We sought to evaluate the impact of cryopreservation of unrelated donor peripheral blood stem cell (PBSC) grafts on engraftment, chimerism, and immune reconstitution in the context of the Covid-19 pandemic. We reviewed stem cell product characteristics and clinical outcomes in 101 patients receiving cryopreserved PBSCs from unrelated donors (URD) between January 1, 2019, and December 31, 2020, compared with 203 patients receiving fresh URD PBSCs. We observed no differences in 6-month overall sur...
Source
#1Christopher J. Gibson (Harvard University)H-Index: 22
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. R. C. Lindsley (Harvard University)H-Index: 1
view all 29 authors...
Background Clonal hematopoiesis (CH) can be transmitted from donor to recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on recipient outcomes and graft alloimmune function is uncertain. Methods We performed targeted error-corrected sequencing on samples from 1727 donors aged 40 or older and assessed the effect of donor CH on recipient clinical outcomes. We measured long-term engraftment of 102 donor clones and ...
Source
#1Kuo-Kai Chin (Brigham and Women's Hospital)
#2Haesook T. Kim (Harvard University)H-Index: 74
Last. Robert J. Soiffer (Harvard University)H-Index: 127
view all 13 authors...
Structured Abstract null null Background null Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality after allogenic hematopoietic stem cell transplantation. Corticosteroid-based therapies are a mainstay of its initial treatment but there is no consensus in how to treat steroid-refractory cGVHD. Ibrutinib is a Bruton Tyrosine Kinase and Interleukin-2 Inducible Kinase inhibitor thought to affect pathways driving cGVHD, and it was approved for the treatment of...
Source
#1Roman M Shapiro (Harvard University)H-Index: 2
#2Grace Birch (Harvard University)
Last. Yohei Arihara (Harvard University)H-Index: 7
view all 28 authors...
Abstract null Background null Responses to conventional donor lymphocyte infusion (DLI) for post-allogeneic hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell-based therapy is a promising modality to treat post-HCT relapse. null Methods null We initiated this ongoing phase 1 trial of adoptively transferred cytokine induced memory-like (CIML) NK cells in patients with myeloid malignancies relapsed after haploidentical HCT. All patients received a donor-d...
Source
#3Erin M. Parry (Harvard University)H-Index: 9
Source
#1Haesook T. Kim (Harvard University)H-Index: 74
#2Brent R. Logan (MCW: Medical College of Wisconsin)H-Index: 67
Last. Daniel J. Weisdorf (UMN: University of Minnesota)H-Index: 142
view all 3 authors...
Abstract With the recent development of transplant-specific composite endpoints for evaluation of allogeneic hematopoietic cell transplantation (alloHCT) outcomes, the use of these novel endpoints is growing rapidly. Combining multiple endpoints into a single endpoint, these composite endpoints appear simple and can be used as a summary measure for overall effectiveness of an intervention. However, all component endpoints may not have equal clinical significance and an intervention may not work ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.